Azelnidipine

Sort by

Azelnidipine Impurity 1

  • CAT Number DCTI-C-1149
  • CAS Number 1360462-97-0
  • Molecular Formula C16H18N2O6
  • Molecular Weight 334.33

General Information

Azelnidipine Impurities and Azelnidipine

Daicel Pharma offers the best-quality Azelnidipine impurities, such as Azelnidipine Impurity 1. They are vital for evaluating Azelnidipine quality, stability, and biological safety. Furthermore, Daicel Pharma specializes in the custom synthesis of Azelnidipine impurities and ensures their worldwide delivery.
Azelnidipine [CAS: 123524-52-7] is a dihydropyridine derivative developed by Sankyo Co., Ltd., Japan. It is a calcium channel blocker that acts slowly to reduce blood pressure. It is a third-generation calcium channel antagonist.

Azelnidipine: Use and Commercial Availability  

Azelnidipine gradually decreases blood pressure in hypertensive patients. It is a vasodilator that has anti-atherosclerotic, neuroprotective, and cardioprotective properties. It is available in oral dosage forms. Various manufacturers sell Azelnidipine under Calblock, Emdip, Azeliren, etc.

Azelnidipine Structure and Mechanism of ActionAzelnidipine

The chemical name of Azelnidipine is 3-[1-(Diphenylmethyl)-3-azetidinyl] 5-isopropyl (±)-2-amino-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate. The chemical formula for Azelnidipine is C33H34N4O6, and its molecular weight is approximately 582.65 g/mol.

Azelnidipine blocks trans-membrane Ca2+ voltage-dependent channels. It results in the relaxation of smooth muscles in vascular cells, causing the reduction of blood pressure.

Azelnidipine Impurities and Synthesis

During the synthesis of Azelnidipine1, impurities may form that may affect the safety and efficacy of the drug. These impurities form during the synthesis, storage, or degradation of Azelnidipine. As a result, Azelnidipine impurities must be controlled and monitored throughout the drug development process.
Daicel Pharma offers a comprehensive Certificate of Analysis (CoA) for Azelnidipine impurities, which includes Azelnidipine Impurity 1. A cGMP-compliant analytical facility furnishes the CoA. It provides complete characterization data2 such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity. We give additional spectral data on request. Daicel Pharma can prepare any unidentified Azelnidipine impurity or degradation product. In addition, Daicel Pharma offers highly purified stable isotope-labeled standards of Azelnidipine for bioanalytical research and BA/BE studies. Customers can expect a complete characterization report on delivery.

References
FAQ's

References

  1. Koike, Hiroyuki; Yoshimoto, Masafumi; Nishino, Hiroshi, Dihydropyridine derivatives, their preparation and their use, EP266922B1, Sep 8, 1993, Sankyo Co., Ltd., Japan, Ube Industries, Ltd. (https://patents.google.com/patent/EP0266922B1/un)
  2. Kawabata, Kiyoshi; Urasaki, Yoko, Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 844, Issue: 1, Pages: 45-52, 2006 DOI: (10.1016/j.jchromb.2006.06.031)

Frequently Asked Questions

The reversed-phase high-performance liquid chromatography (RP-HPLC) method helps identify the impurities of Azelnidipine.

Oxidative conditions are responsible for the significant degradation of Azelnidipine.

It is essential to monitor and detect impurities of Azelnidipine for drug safety and quality.

Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.

Back to Top
Product has been added to your cart